Latest news - Johnson & Johnson
Oct 10, 2024 · A collection of stories that highlight the way Johnson & Johnson is making an impact in the lives of its consumers, and the latest press releases from the company.
Press Releases - Johnson & Johnson
Dec 16, 2024 · Explore all Johnson & Johnson published press releases by date and/or topic of news.
Johnson & Johnson Announces Plans to Accelerate Innovation, …
Nov 12, 2021 · Johnson & Johnson would Remain a Global Leader in Healthcare, Focused on Major Unmet Medical Needs and Materially Advancing Standard of Care through Biopharmaceutical and Medical Device Innovation and Technology
Johnson & Johnson Reports Q3 2024 Results | Johnson & Johnson
Oct 15, 2024 · NEW BRUNSWICK, N.J.--(BUSINESS WIRE)-- Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2024. “Johnson & Johnson’s strong results in the third quarter reflect the unique breadth of our business and commitment to delivering the next wave of healthcare innovation,” said Joaquin Duato, Chairman and Chief Executive Officer.
Media Center - Johnson & Johnson
Read the latest press releases from Johnson & Johnson, find our press contacts and see our latest social media posts.
Johnson & Johnson Announces Real-World Evidence and Phase 3 …
Sep 21, 2021 · Johnson & Johnson single-shot vaccine showed strong and long-lasting protection in the real world The largest real-world evidence study for a COVID-19 vaccine reported to date in the U.S. demonstrated stable vaccine effectiveness of 79 percent (CI, 77%-80%) for COVID-19-related infections and 81 percent (CI, 79%-84%) for COVID-19-related ...
News | Johnson & Johnson - Investors
You should view the News section and the most recent SEC Filings in the Investor section in order to receive the most current information made available by Johnson & Johnson Services, Inc. Contact us with any questions or search this site for more information.
What you need to know about J&J's Q2 2024 earnings - Johnson …
Jul 17, 2024 · What you need to know about Johnson & Johnson’s 2024 second quarter earnings. Here’s an infographic breakdown of the company’s second quarter earnings results, including key highlights from its Innovative Medicine and MedTech businesses.
TECVAYLI® (teclistamab-cqyv) demonstrates potential as frontline ...
Dec 8, 2024 · Johnson Johnson (NYSE:JNJ) today announced new frontline data featuring TECVAYLI ® (teclistamab-cqyv) from two investigational studies in patients with newly diagnosed multiple myeloma (NDMM) in induction and maintenance settings.
Icotrokinra delivered an industry-leading combination of …
Nov 18, 2024 · Johnson Johnson (NYSE: JNJ) today announced positive topline results from ICONIC-LEAD a , a pivotal Phase 3 investigational study of icotrokinra (JNJ-2113), the first targeted oral peptide that selectively blocks the IL-23 receptor, in adults and adolescents 12 years of age and older with moderate to severe plaque psoriasis (PsO).